Literature DB >> 6215432

Systemic absorption of clindamycin hydrochloride after topical application.

M Barza, J A Goldstein, A Kane, D S Feingold, P E Pochi.   

Abstract

Clindamycin has become a highly popular drug for the topical therapy of acne; however, the extent to which it is systemically absorbed from the skin has has not been established. We measured the serum level and urinary excretion of clindamycin on the third day and the twenty-seventh day of therapy in thirteen patients who were applying 1% clindamycin hydrochloride topically for acne. There was no detectable antibiotic in the serum of any subject (less than 0.4 microgram/ml); in contrast, clindamycin was found in the urine of ten of the thirteen patients. There was marked intersubject variation in the urinary excretion of the drug, ranging from less than 10 to 500 micrograms/day. However, there was a highly significant correlation (p less than 0.0001) for a given subject between excretion values on days 3 and 27. There was no correlation between urinary excretion of clindamycin and either racial pigmentation or severity of acne in this relatively small group of patients. After topical application of 1% clindamycin hydrochloride, an average of 4% to 5% of clindamycin appears to be absorbed systemically, but greater amounts are absorbed in some individuals.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6215432     DOI: 10.1016/s0190-9622(82)70109-4

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  3 in total

1.  [Acne therapy in pregnancy].

Authors:  C Bayerl
Journal:  Hautarzt       Date:  2013-04       Impact factor: 0.751

Review 2.  [Management of acne vulgaris: focus on clindamycin and zinc].

Authors:  H C Korting; C Schöllmann
Journal:  Hautarzt       Date:  2009-01       Impact factor: 0.751

Review 3.  Transdermal penetration of topical drugs used in the treatment of acne.

Authors:  Andrea Krautheim; Harald Gollnick
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.